Pozen (Nasdaq: POZN) will receive a $25 million payment from its drug development partner Astra Zeneca within the next 20 days, the pharmaceutical firm said Friday.

The payment is due now that Vimovo, the pain reliever Pozen and AstraZeneca developed together, has received marketing and pricing approval in the United Kingdom.

Get the latest news alerts: Follow LTW at Twitter.